Motixafortide Evidence Guide
Motixafortide (Aphexda) is FDA-approved in combination with G-CSF for hematopoietic stem cell mobilization prior to autologous transplantation in multiple myeloma. The Phase 3 GENESIS trial showed significantly more CD34+ cells mobilized with fewer apheresis sessions versus G-CSF alone. A well-evidenced stem cell mobilization enhancer for a specific transplant medicine context.
Our Take
Motixafortide (Aphexda) is FDA-approved in combination with G-CSF for hematopoietic stem cell mobilization prior to autologous transplantation in multiple myeloma. The Phase 3 GENESIS trial showed significantly more CD34+ cells mobilized with fewer apheresis sessions versus G-CSF alone. A well-evidenced stem cell mobilization enhancer for a specific transplant medicine context.
- Best for
- Hematopoietic stem cell mobilization (multiple myeloma transplant), CXCR4 antagonist pharmacology
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 1.25mg/kg subcutaneous 10-14 hours before each apheresis session
Benefits and Evidence
- Stem Cell Mobilization: Level A, includes human evidence - Phase 3 GENESIS trial demonstrated that motixafortide + G-CSF enabled 92% of patients to reach target CD34+ cell count of >=6 x10^6 cells/kg in <=2 apheresis sessions, vs 26% with placebo + G-CSF.
- Engraftment Success: Level A, includes human evidence - Patients transplanted with motixafortide-mobilized grafts showed successful neutrophil and platelet engraftment comparable to standard mobilization approaches.
- Injection Site Reactions: Level A, includes human evidence - Injection site reactions including erythema, pain, and pruritus occurred in approximately 56% of patients but were generally mild to moderate.
Side Effects and Warnings
- Injection site reactions (erythema, pain, pruritus)
- Diarrhea
- Musculoskeletal pain
- Dizziness
- Nausea
- Hypersensitivity reactions
- Anaphylaxis and serious hypersensitivity reactions reported - observe for at least 1 hour after injection
- Splenic enlargement/rupture possible with G-CSF combination
Research Dosage References
- <strong>Subcutaneous injection</strong> - 1.25 mg/kg - Single dose on day of apheresis - Administered after G-CSF priming (typically 4 days of G-CSF before motixafortide). Given on the morning of planned apheresis, approximately 10 hours before collection.
Mechanism of Action
Motixafortide mobilizes stem cells through CXCR4 receptor antagonism: 1. CXCR4 high-affinity antagonism: Binds to and blocks CXCR4 receptors on hematopoietic stem and progenitor cells with high affinity and slow off-rate kinetics. 2. CXCL12/SDF-1 axis disruption: Blocks the interaction between CXCR4 on stem cells and CXCL12 (stromal cell-derived factor 1) expressed by bone marrow stromal cells, releasing stem cells from the marrow niche. 3. Rapid mobilization: When combined with G-CSF, produces rapid and robust mobilization of CD34+ hematopoietic stem cells into peripheral blood within hours. 4. Enhanced collection: Increases the yield of CD34+ cells during apheresis, often achieving target cell counts in fewer collection sessions.
Legal Status
FDA-approved (September 2023) in combination with G-CSF for mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma. Available by prescription only. Marketed as Aphexda by BioLineRx.
Primary Sources
- Motixafortide and G-CSF for stem cell mobilization in multiple myeloma (GENESIS). N Engl J Med, 2023.
- BL-8040 (motixafortide): a novel CXCR4 antagonist for stem cell mobilization. Clin Cancer Res, 2019.
Popular Questions
- Motixafortide Benefits: Evidence, Verdict, and Limits
- Motixafortide Side Effects: Safety Signals and Warnings
- Motixafortide Research Dosage: Published Protocol Reference
- Is Motixafortide Legit? Evidence Grade and Plain-English Verdict
- Motixafortide Legal Status: Approval, Research Use, and Regulatory Notes